Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06935591 · ClinicalTrials.gov registry record · NA

Artificial Intelligence Mapping and Ablation of Non-Pulmonary Vein Electrical Drivers of AF Study

A NA study of Atrial Fibrillation (AF), sponsored by Vektor Medical.

Recruiting
Registry status
NA
Development phase
423
Enrollment target
13
Study locations

NCT06935591 is a NA study of Atrial Fibrillation (AF) that is actively recruiting participants, run by Vektor Medical. The registered enrollment target is 423 participants, below the 695-participant average among 17 other Atrial Fibrillation (AF) trials with a reported enrollment target (39% lower). The trial reports 13 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06935591, a NA study of Atrial Fibrillation (AF), is actively recruiting participants, sponsored by Vektor Medical.

RECRUITING
Registry status
NA
Development phase
423 participants
Enrollment target
13
Study locations

Study Summary

The goal of this clinical trial is to compare the use of the Vektor Computational ECG Mapping System (vMap®) with pulmonary vein isolation (PVI), to using PVI alone, to treat Atrial Fibrillation (AF) in adults. Participants will have a 50/50 or 1 out of 2 chance of being placed in the treatment or control arm. The control arm of the study involves PVI alone for ablation procedure(s). The treatment arm involves the use of vMap mapping in addition to PVI to plan ablation procedure(s).

Conditions Studied

Atrial Fibrillation (AF)

Interventions

  • PROCEDURE Pulmonary Vein Isolation
  • DEVICE vMap® + Pulmonary Vein Isolation

Study Locations (13)

Florida

  • BayCare Health System - Clearwater
  • Baptist Health Jacksonville - Jacksonville
  • USF Health - Tampa

Georgia

  • Piedmont Heart of Athens - Athens
  • Piedmont Heart Institute - Atlanta

Ohio

  • OhioHealth - Columbus
  • University of Toledo Medical Center - Toledo

Arkansas

  • Arrhythmia Research Group - St. Bernards - Jonesboro

Indiana

  • Indiana University - Indianapolis

Kentucky

  • Baptist Health Lexignton - Lexington

New York

  • Westchester Medical Center - Valhalla

Pennsylvania

  • Penn Presbyterian - Philadelphia

Trial Details

FieldValue
Enrollment Target 423 participants
Start Date 2025-06-27
Est. Completion 2027-12
Phase NA

Sponsor

Vektor Medical

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06935591

The ClinicalTrials.gov registry entry for NCT06935591 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 423 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 695-participant average among 17 other Atrial Fibrillation (AF) trials with a reported enrollment target (39% lower). The listed sponsor is Vektor Medical, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Atrial Fibrillation (AF) appearing as the primary indexed condition, and to 2 interventions - of which Pulmonary Vein Isolation is the first listed.

NCT06935591 reports 13 study locations spanning 9 distinct geographic areas - top geographies include Florida, Georgia, Ohio.

Frequently Asked Questions

What is clinical trial NCT06935591 about?

NCT06935591 is a clinical study titled "Artificial Intelligence Mapping and Ablation of Non-Pulmonary Vein Electrical Drivers of AF Study". The goal of this clinical trial is to compare the use of the Vektor Computational ECG Mapping System (vMap®) with pulmonary vein isolation (PVI), to using PVI alone, to treat Atrial Fibrillation (AF) in adults. Participants will have a 50/50 or 1 out of 2 chance of being placed in the treatment or ...

What is the current status of trial NCT06935591?

This trial is currently recruiting. It is a NA study. The enrollment target is 423 participants. The study started on 2025-06-27. Estimated completion is 2027-12.

What conditions does trial NCT06935591 study?

This clinical trial studies the following conditions: Atrial Fibrillation (AF).

What interventions are being tested in trial NCT06935591?

The interventions under investigation include: Pulmonary Vein Isolation (PROCEDURE), vMap® + Pulmonary Vein Isolation (DEVICE).

Who is sponsoring clinical trial NCT06935591?

This trial is sponsored by Vektor Medical, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06935591 being conducted?

This trial has 13 study locations across Arkansas, Florida, Georgia, Indiana, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Atrial Fibrillation (AF)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Atrial Fibrillation (AF)

All registered trials for this condition

Arkansas

All trials with a study site in Arkansas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.